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Background: Long-term follow-up after transition to oral agents from parenteral
prostanoid therapy has not been well characterized.
Methods: We reviewed our long-term experience after oral transitioning in patients with
pulmonary hypertension. Patients were weaned off parenteral therapy based on a pre-
determined outpatient protocol. Data were collected retrospectively after transition had
taken place.
Results: Twenty-one transitioned patients were identified. Fifteen patients (71.4%) were
successfully transitioned (ST): 7 to bosentan, 5 to bosentan and sildenafil, and 3 to
sildenafil. Six patients failed transition (FT). None of the patients in the FT group received
sildenafil. Prior to transition attempt, patients in the ST group were treated with
parenteral agents for a mean of 26 months vs. 16 months in the FT group (p ¼ 0.12).
Maximal epoprostenol dose was low in both groups (ST 17.8ng/kg/min vs. FT 14.5ng/kg/min).
Mean duration of oral therapy prior to transition was 11 months. After a mean follow-
up of 24 months, most patients on both groups were able to maintain stable 6min walk
distance and hemodynamics. FT was not associated with short- or long-term adverse
events.
Conclusions: Oral transition from parenteral prostanoid agents can be safely done in a
selected group of patients. Most patients are able to maintain stable functional class and
hemodynamics at long follow up regardless of success of transition attempt. CombinationElsevier Ltd. All rights reserved.
tance; 6MWT, 6-min walk test; BNP, type-B natriuretic peptide; CI, cardiac index; CO, cardiac output;
rterial hypertension; PAP, pulmonary arterial pressure; PH, pulmonary hypertension; PVR, pulmonary
rostanoid agents; RVSP, right ventricular systolic pressure; ST, successful transition; WHO, World Health
445 2510; fax: +1 216 445 1878.
.A. Minai).
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E. Diaz-Guzman et al.682therapy with sildenafil appears to be associated with higher likelihood of successful
transitioning.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Pulmonary arterial hypertension (PAH) is a disease char-
acterized by progressive pulmonary vasculopathy that
results in right heart failure and death.1 Patients with
severe pulmonary hypertension (PH) and poor functional
class (World Health Organization [WHO] class III and IV) are
considered candidates for treatment with parenteral pros-
tanoid agents (PGI2). Although parenteral therapy has been
shown to improve hemodynamics and survival in patients
with severe PAH,2 treatment with these agents poses
numerous challenges including an elevated cost, the need
for central venous access, risk of thrombosis and infections,
and several common adverse drug effects.3,4 Moreover, drug
interruption can result in unfavorable outcomes such as
need for hospitalization or even death.5
The development of oral agents such as the endothelin
receptor antagonists and phosphodiesterase inhibitors,
offers new treatment options. Physicians currently face
the challenge of determining if some patients on intrave-
nous therapy can be safely transitioned to oral medications.
Previous reports have shown that epoprostenol can be
transitioned to oral therapy in carefully selected patients
and that some patients discontinuing PGI2 may exhibit
clinical and hemodynamic stability after short- and medium-
term follow up.6–8 Despite these promising reports, there is
lack of understanding about the factors that would predict a
successful transition to oral agents and there are no
guidelines to safely direct this process. Attempts at
transition remain guided by scant literature especially as it
relates to long-term outcomes after transition.9,10 In
addition, little is known about the risks of an unsuccessful
transition and if this is associated with worse outcomes. Our
report is an attempt to further investigate these unan-
swered questions.Methods
The study was approved by our Institutional Review Board.
We performed a retrospective chart review to identify
patients in whom an attempt was made to wean off PGI2
with the addition of oral therapy. Transition from PGI2 was
attempted only in patients who were clinically stable (WHO
class I–III, no evidence of overt right heart failure
(exertional syncope, worsening lower extremity edema,
jugular venous distension, hepatomegaly), stable 6-min walk
distance (6MWD), and stable dose of PGI2 for the preceding
month) and was based on patient’s preference for oral
therapy, or severe or recurrent delivery device complica-
tions such as catheter-related infections or severe infusion
site pain.
Prostanoid analogs were weaned according to an out-
patient weaning protocol (epoprostenol 3 ng/kg/min per
week and treprostinil 4–6 ng/kg/min per week) untilpatients were at a dose of p8 ng/kg/min or p30% of
baseline dose. Clinicians were advised to wait for at least 2
months after addition of the oral agent(s) prior to initiation
of prostanoid weaning and to perform right-sided heart
catheterization prior to discontinuation of the PGI2. After
initial reduction of the prostanoid doses and once patients
reached the goals mentioned above, patients were admitted
to an intensive care unit and the PGI2 was titrated down at
the rate of 1 ng/kg/min every hour as long as hemodynamics
remained stable. During the weaning period and after
discontinuation of PGI2, frequent telephone contact was
maintained with the patients and they were evaluated
clinically and underwent 6-min walk test (6MWT), trans-
thoracic echocardiography, and type-B natriuretic peptide
(BNP) testing every 2–3 months. Patients able to successfully
transition to oral agents alone and not require re-institution
of PGI2 therapy at the time of data collection, were
included in the successful transition (ST) group, whereas
those not able to tolerate the discontinuation of parenteral
prostanoids initially or those requiring the re-institution of
parenteral prostanoids were included in the failed transition
(FT) group. Those who failed within 3 months of disconti-
nuation were categorized as ‘early failures’ and those who
failed more that 3 months after discontinuation were
categorized as ‘late failures’.
Patients were followed and evaluations were performed
prospectively, however, data were not captured or recorded
until the summer of 2006 after institutional review board
approval. At that point, an attempt at transition from PGI2
therapy to oral agents had been made in 21 patients with
PH.
Statistical analysis
All quantitative variables are summarized as mean7
standard deviation (SD). Group comparisons were performed
by w2 tests or Fisher’s exact test with respect to categorical
variables. Group comparisons with respect to quantitative
and ordinal variables were performed using Wilcoxon rank
sum test and T-test.
Results
Clinical features prior to transition (Table 1)
We identified 21 patients who had received treatment with
PGI2 [intravenous epoprostenol (n ¼ 17) and treprostinil
(2 intravenously and 2 subcutaneously)] in whom transition
to oral agents was attempted. Fifteen patients (age 47.37
12.6, mean7SD; 11 female/4 male) were successfully
transitioned (ST group) to oral agents and 6 patients (age
36.275.9, mean7SD; 4 female/2 male) failed to be transi-
tioned (FT group) and required continuation or re-institution
of therapy with parenteral agents. Demographics, etiology
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Table 1 Demographics and pulmonary hypertension targeted therapy at baseline and during transition.
Patient
no.
Age Sex Diagnosis Drug d/c Reason for d/c PGI2
(mo)
Max PGI2
dose
Oral txy
(mo)
Tx at
d/c
Successful transition (ST) group
1 39 M HIV EPO Intolerable PGI2 side
effects
28 19 11 B
2 38 F SLE EPO Thrombocytopenia 9 18 0 B
3 34 F SLE EPO Recurrent line infection 37 13 24 B
4z 61 F Appetite-
suppressant
EPO/TREP Patient preference 28 17 13 B+S
5 55 F IPAH EPO Intolerable PGI2 side
effects
26 16 11 B+S
6 35 F IPAH EPO Intolerable PGI2 side
effects
8 10 4 B
7 54 F SLE TREP Severe site pain 20 42 3 B
8z 27 F Familial EPO/TREP Patient preference 83 29 16 B+S
9 60 F CHD EPO Intolerable PGI2 side
effects
34 21 44 B
10 46 F SLE EPO Intolerable PGI2 side
effects
4 10 0 S
11 45 M CTEPH EPO Patient preference 38 13 5 S
12 41 M Porto-pulmonary EPO Patient preference 8 14 1 B
13 52 M Porto-pulmonary EPO Patient preference 42 8 1 S
14 76 F IPAH EPO Patient preference 19 32 17 B+S
15 47 F Sarcoidosis EPO Recurrent line infection 28 29 15 B+S
Mean7SD 47.3712.6 26717 1877.6 11712
Failed transition (FT) group
1 42 F IPAH EPO Intolerable PGI2 side
effects
8 5 3 B
2 38 F SLE EPO Patient preference 35 13 26 B
3 39 F IPAH TREP Patient preference 15 42.5 14 B
4 35 M Scleroderma EPO Patient preference 12 17 6 B
5 38 M CHD EPO Patient preference 16 24 5 B
6 25 F IPAH EPO Intolerable PGI2 side
effects
8 13.5 5 B
Mean7SD 36.275.9 16710 14.576.9 1079
Abbreviations: d/c: discontinued; PGI2: prostanoid analogues; mo: months; Tx: treatment; F: female; M: male; EPO: epoprostenol (in
ng/kg/min); TRE: treprostinil (in ng/kg/min); B: bosentan; S: sildenafil; and NA: not available.
Total duration of parenteral prostanoid therapy prior to discontinuation.
yDuration of bosentan and/or sildenafil prior to discontinuation of parenteral prostanoids.
zPatients originally on epoprostenol and then switched to treprostinil.
Long-term experience after transition from parenteral 683of PH, reason for discontinuation of PGI2, and oral therapy
used prior to transition are shown in Table 1. The majority of
patients had PAH (90.5%) with idiopathic pulmonary arterial
hypertension (IPAH) and systemic lupus erythemathosus
associated PAH (SLE-PH) accounting for 29% and 24% of
the group, respectively. One patient had PH associated
with sarcoidosis and another had PH secondary to chronic
thromboembolic disease. Patients in the ST group were
older than patients in the FT group (47.3712.6 vs.
36.275.9 years old, respectively; p ¼ 0.013). Eight patients
(6 ST and 2 FT) were started on PGI2 before bosentan was
commercially available (December 2001). Of these, 6
patients had significant hemodynamic compromise and poor
functional class and would have been started on PGI2 even if
bosentan had been available.Transition process (Tables 1 and 2)
The most common reasons for attempted transition
included patient preference (n ¼ 10) and intolerable pros-
tanoid side effects (n ¼ 9). Patients in the ST group tended
to have longer duration of prostanoid therapy prior to
transitioning, but this difference did not reach statistical
significance (26717 months in the ST group vs. 16710
months in the FT group, p ¼ 0.12). The weaning period prior
to discontinuation attempt was similar between the groups
(1.671.5 in the ST group vs. 1.770.4 in the FT group,
p ¼ 0.42). The maximal epoprostenol dose (17.877.6 ng/
kg/min in the ST group vs. 14.576.9 ng/kg/min in FT group,
p ¼ 0.2) was similar between the 2 groups. The duration of
oral therapy before transition was similar in both groups
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Table 2 Clinical data and hemodynamics of ST group and FT group before transition.
Patient WHO
baseline
WHO
d/c
6MWT
baseline
6MWT
d/c
BNP
baseline
BNP d/c mPAP
baseline
mPAP
d/c
CI
baseline
CI d/c PVR
baseline
PVR
d/c
Successful transition (ST) group
1 III II 419 608 62 5 50 26 2.7 4.1 6.5 2
2 IV III 133 335 1070 618 48 36 1.7 2.8 11 4
3 III II 404 433 NA 142 45 22 2.1 3.4 9 NA
4 III III 258 277 204 183 72 46 1.7 2.37 15.5 8.45
5 III II 265 530 NA 239 63 53 1.5 2.2 17 9.7
6 IV II 422 456 NA NA 43 54 2.06 3.46 8 6
7 III II 472 515 NA NA 59 NA 2.8 NA 9 NA
8 IV II 367 401 NA 192 110 NA 1.2 NA 12 NA
9 IV II 303 465 1160 184 72 29 2.3 3.8 9.3 3
10 III III 244 287 86 80 50 34 1.8 NA 10 NA
11 II II 479 523 125 85 85 49 2.4 2.9 7.8 5.5
12 II II NA 479 NA 81 38 NA 3.9 NA 3 NA
13 II II 419 561 9 41 50 36 2.2 4.4 8 2.225
14 III III 323 224 580 355 65 36 1.7 3.58 14 2
15 IV III 192 322 580 9 65 NA 1.6 NA 15 9
Mean
7SD
II 20%, III
47%, IV 33%
II 67%,
III 33%
3367107 4287115 4317442 1707167 61719 38711 2.170.7 3.370.7 1074 5.273
Failed transition (FT) group
1 III II 392 430 NA 61 64 52 2.2 3.2 16.0 10.0
2 III II 354 456 NA 319 55 NA 1.7 NA 13.0 NA
3 III II 454 564 NA 33 40 50 2.1 3.4 10.0 7.0
4 III III 338 384 NA NA 61 17 1.5 3 17.1 2.0
5 IV II 399 460 138 65 58 59 1.8 2.1 45.4 31.1
6 III II 378 521 135 23 35 36 2.1 2.7 3.4 5.0
Mean
7SD
III 83%, IV
17%
II 83%,
III 17%
386741 469764 137 1007124 52712 43717 1.970.3 2.870.5 17.5714
11711.6
Abbreviations: baseline: values at the time of original diagnosis of PH; d/c: last values prior to discontinuation of parenteral prostanoid
therapy; 6MWT: 6-min walk test (in m); BNP: B-type natriuretic peptide (pg/mL); mPAP: mean pulmonary artery pressure (mmHg); CI:
cardiac index (L/min/m2); and PVR: pulmonary vascular resistance (Woods units).
These patients additionally had a left heart catheterization that confirmed a normal pulmonary capillary wedge pressure
(o18mmHg) and normal LVEDP o12mmHg).
E. Diaz-Guzman et al.684(11712 months in the ST vs. 1079 months in the FT group;
p ¼ 0.78). All 8 (of 15; 53%) patients receiving sildenafil
alone (N ¼ 3) or in combination with bosentan (N ¼ 5), were
ST off parenteral therapy (p ¼ 0.0456).
Table 2 depicts relevant clinical and hemodynamic
features at the time of original diagnosis of PH prior to
initiation of PGI2 (baseline) and during the transition period.
At baseline, both groups had severe PH (mPAP 61 and
52mmHg [p ¼ 0.31], and mean CI 2.1 and 1.9 L/min/m2
[p ¼ 0.64] in the ST and FT groups, respectively). When the
decision to discontinue PGI2 was made, 10 out of 15 (67%) in
the ST group and 5 out of 6 patients (83%) in the FT group
were functional class II. No significant differences were
noted between the STand FT groups for 6MWD, BNP, or right
ventricular systolic pressure (RVSP) at the time the decision
to transition was made (p ¼40.05 for all measures).
Similarly, in patients who underwent right heart catheter-
ization just prior to discontinuation of PGI2, no significant
differences were noted between the ST and FT groups in
terms of cardiac index, mean pulmonary artery pressure, or
pulmonary vascular resistance (p ¼40.05 for all measures).Follow up data after transition (Table 3)
Follow up data on both groups is shown in Table 3 and
Figures 1 and 2. Total follow up was 24.7713.6 months in
the ST group and 3075.6 months in the FT group. Most
patients who were ST experienced stable 6MWD and RVSP
throughout follow up. The same was true for patients who
did not tolerate weaning off prostanoid therapy. In the ST
group, 5 patients showed a decline in their 6MWD and/or
their WHO functional class during follow-up. In 3 of these
patients, the deterioration was not felt to be significant by
the treating physician and 1 (patient no. 15) patient refused
re-initiation of PGI2 therapy. The last patient (patient no. 5)
remained stable after transition for approximately 3 years
and subsequently moved to high altitude, against medical
advice, and died of pneumonia. There were no statistically
significant differences in these clinical parameters between
the ST and FT groups throughout follow up (p40.05 for
all comparisons). None of our patients have required
discontinuation of bosentan due to elevation in liver
function tests.
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Table 3 Follow up variables and outcomes of ST (N ¼ 15) and FT (N ¼ 6) groups.
Patient
no.
F/u Mo WHO 6MWT RVSP BNP Outcome
At d/c 6 mo Last At d/c 6 mo Last At d/c 6 mo Last At d/c 6 mo Last
Successful transition (ST) group
1 41 II II II 608 NA 448 50 41 38 62 16 11 Alive
2 41 III III III 335 NA 197 48 NA 54 1070 NA 285 Alive
3 29 II II II 433 370 410 65 34 34 NA 109 14 Alive
4 42 III III III 277 196 162 81 80 86 204 161 67 Alive
5 34 II II IV 530 487 343 72 93 79 NA 128 361 Deady
6 49 II II II 456 454 506 45 50 59 NA 11 14 Alive
7 14 II II II 515 565. 535 22 26 25 NA 154 80 Alive
8 27 II II II 401 NA 436 103 NA 120 NA NA 51 Alive
9 17 II III II 465 419 447 43 37 38 1160 125 264 Alive
10 14 III III III 287 260 261 97 NA 73 86 NA 78 Alive
11 11 II II II 523 586 587 70 69 83 125 42 52 Alive
12 12 II II II 479 NA 447 52 57 92 NA 70 157 Alive
13 13 II II II 561 548 549 54 69 28 9 17 22 Alive
14 12 III III II 224 335 335 51 43 43 580 129 129 Alive
15 14 III IV IV 322 213 213 41 62 87 580 5 477 Alive
Mean7SD 24.7713.6 II 67%, III
33%
II 60%, III 33%, IV
7%
II 67%, III 20%, IV 13% 4287115 4037140 3927134.5 60722 55720 63728 4317442 81760 137.57144
Failed transition (FT) group
1z 50 II II II 430 Na 337 100 82 87 61 18 73 Alive
2 25 II II II 456 444 590 69 81 64 319 261 72 Alive
3 14 II II I 564 559 552 70 48 36 33 69 45 Alive
4z 44 III I IV 384 428 251 NA NA 101 NA 22 274 Dead
5 22 II III III 460 407 404 56 78 92 65 60 60 Alive
6 25 II III II 521 543 598 56 65 45 23 13 5 Alive
Mean7SD 30.075.6 II 83%, III
17%
I 17%, II 50 %, III
33%
I 17%, II 50%, III 17%, IV
17%
469764 476770 4557146 70718 71714 71726 1007124 74795 88794
Abbreviations: WHO: World Health Organization functional class; 6MWT: 6-min walk test (m); RVSP: right ventricular systolic pressure (mmHg); BNP: B-type natriuretic peptide (pg/mL);
DC: last value prior to discontinuation of parenteral prostanoids; and Last: most recent value.
Total follow up time in months after prostanoid therapy discontinuation.
yPatient moved to high altitude and died with pneumonia approximately 34 months after prostanoid therapy was discontinued.
zThese patients failed aproximately 39 and 24 months after epoprostenol discontinuation, repectively.
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Figure 1 Six-minute walk distance and RVSP-successful: mean values with 95% confidence intervals.
Figure 2 Six-minute walk distance and RVSP-unsuccessful: mean values with 95% confidence intervals.
E. Diaz-Guzman et al.686Transition failures (FT group) (Table 3)
Six patients failed to successfully transition to oral agents or
required re-institution of PGI2 after initial transition. Two
patients could not tolerate discontinuation and were
continued on PGI2. Two patients each, required re-institu-
tion of PGI2 within 3 months (early failure) and more than 3
months (late failure) after transitioning to oral therapy,
respectively. After transition, 1 patient in the FT group
(patient no. 1) completely discontinued her bosentan for 22
months, against medical advice, after which she deterio-
rated and was started on PGI2. She has regained her baseline
functional status and is currently WHO II. Patient no. 4
deteriorated clinically after being off PGI2 for 25 months.He died of worsening PH 28 months after the re-initiation of
PGI2 therapy.Discussion
Our study presents the results of a series of patients who
were transitioned from prostanoid agents to oral agents
according to a pre-determined out-patient weaning proto-
col. Our results indicate that selected patients with PH who
are clinically stable on low doses of parenteral prostanoid
agents may be safely transitioned to oral agents with good
long-term results. We found that the use of sildenafil, alone
or in combination with bosentan, was associated with a
ARTICLE IN PRESS
Long-term experience after transition from parenteral 687higher likelihood of a successful transition. We also found
that patients that FT were not affected adversely by the
attempt, and were able to reach their baseline clinical
status with the resumption of prostanoid therapy.
It is important to emphasize that transition to oral therapy
from parenteral agents in patients with PH is a complex
process that requires careful monitoring and close follow up
and should only be attempted at experienced centers. There
is currently no consensus about which patients should be
candidates for transitioning to oral agents and such attempts
remain guided by case reports or small case series. Table 4
summarizes the available adult experience with transition
from prostanoid therapy to oral agents.
Predictors of successful transition are difficult to identify
since the criteria for attempting a transition have varied
between reports. Despite these differences, all studies have
tended to include patients that are ‘clinically stable’ in
WHO classes I–III, on stable doses of prostanoid analogs, andTable 4 Transition from PGI2 to oral agents in adult patients:
Kim et al.6 Suleman and
Frost8
S
No. patients 4 23 2
No. ST (%) 4 (100%) 11 (47.8%) 7
Design Retrospective Prospective P
Criteria prior to
weaning
Normalization of
PAP on
epoprostenol
Infrequent
increase in PGI2
dose, FC II,III, no
heart failure
S
d
a
c
Mean PGI2
duration (mo)
68.4 ST 35.2 S
FT 38.4 3
Mean max PGI2
dose (ng/kg/min)
40.5 ST 25.9 S
FT 40.1 F
At wean, mean:
6MWD (m) N/A 361.8 3
mPAP (mmHg) 21 65.8/84.1 3
CI (L/min/m2) 2.85 CO 4.4 (both) N
PVR (units) NA NA N
Oral therapy CCB ¼ 1 Bosentan B
CCB+Sild+
B ¼ 1
CCB+B ¼ 1
B ¼ 1
Mean oral therapy
duration (mo)
10 3 6
Mean follow up
(mo)
11 9.6 1
Adverse events of
transitioning
None 2 late failures, no
deaths
4
S
Abbreviations: ST: successful transition; FT: failed transition; PGI2:
walk distance; mPAP: mean pulmonary artery pressure; CI: cardiac ind
calcium channel blockers; Sild: sildenafil; B: bosentan; and FC: func
Data separated by ‘‘/’’ indicates ST/FT groups.without evidence of overt right-sided failure. Most previous
studies8,10 have not reported results of right heart cathe-
terization prior to initiation of PGI2 therapy for individual
patients. Contrary to 1 previous report,9 we found that
hemodynamics at the time of initial diagnosis of PH
(‘baseline’ in Table 2) were not useful as guides to
differentiate between those who would or would not be
able to make a successful transition. This stands to reason
since many of these patients were on parenteral therapy for
years prior to attempted discontinuation. Patients with
normal6 or near normal9,10 hemodynamics with the use of
prostanoid agents have been reported to have better long-
term outcomes. Although we found no significant differ-
ences in hemodynamic parameters among the ST and FT
groups, patients who made a successful transition had lower
mPAP and PVR and a higher CI prior to discontinuation. At
the time of PGI2 discontinuation, 5 patients in the ST group
had a PVRp4 units and all but 4 had a mPAP p36mmHg.summary of the available literature.
teiner et al.9 Johnson et al.10 Current report
2 15 21
(31.8%) 10 (66.6%) 15 (71.4%)
rospective Retrospective Retrospective
table FC, o10%
ecrease in 6MWD
nd no PGI2 dose
hanges
Stable FC, no
increase in PGI2,
oral therapy at
least 3 months
FC I, II, or III,
stable 6MWD,
stable prostanoid
dose, no right
heart failure, oral
therapy at least 2
months
T 41 FT 45.1 ST 26
6 FT 16
T 25.5 23.2 ST 18
T 37.67 FT 14.5
17.9/294 420 427.7/469.1
8/56 35.8 38.2/42.8
A CO 4.9 2.1/1.9
A 6.2 10.3/17.5
osentan Bosentan 11 ST: B ¼ 7 S ¼ 3
Sildenafil 2 B+Sild ¼ 5
FT: B ¼ 6
4.5 11
7.7 29.9 27.3
deaths, 2 were
T
2 late failures, no
deaths
1 late death due
to pneumonia in
ST and 1 death in
FT
prostanoid therapy; mo: months; Max: maximum; 6MWD: 6-min
ex; PVR: pulmonary vascular resistance; NA: non-available; CCB:
tional class.
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o30mmHg and PVRo4 units had good long-term outcomes
on oral therapy. Other reports8,9 have also found that
patients able to make the transition successfully were more
likely to have lower pulmonary arterial pressures than those
who could not.
It is unclear if underlying disease has an impact on the
rate of success during the transition process. Most of the
literature relating to transition from parenteral prostanoids
to oral agents is in patients with IPAH. Four of our successful
transitions were patients with SLE and the only scleroderma
patient failed to transition. Johnson et al.10 attempted
transition in 3 patients with SLE-PH and were successful in
all 3 cases. This information is not provided in the other case
series since patients are reported under the generic
diagnosis of connective tissue diseases. Contrary to exten-
sive experience with scleroderma-associated PAH,11,12 we
have recently reported13 sustained long-term improvement
in hemodynamics and functional capacity in patients with
SLE-PH. Whether patients with SLE-PH represent a group
that lends itself to favorable long-term outcomes after
transition to oral agents requires further study.
Maximum prostanoid dose, duration of prostanoid therapy,
and duration of oral therapy are quite variable between the
various reports and their role in terms of predicting success or
failure requires further clarification. In our study the mean
duration of prostanoid therapy before transition was longer in
the group that had a successful transition, although this
difference was not statistically significant (26 months vs. 16
months, p ¼ 0.12). This suggests that longer duration of
prostanoid therapy might be associated with successful
weaning, maybe because longer exposure to these agents
allows for some regression of pulmonary vascular remodeling.
This, of course, remains highly speculative. Tendency for
longer duration of prostanoid therapy to predict weaning
success was seen by Steiner et al.9 Contrary to this Suleman
et al.9 found an increased trend for longer duration of
prostanoid use in patients failing to transition successfully.
Duration of oral therapy prior to successful discontinuation of
prostanoid therapy has varied among reports, ranging from 3
to 11 months. Our experience and the small series by Kim et
al.6 suggest that longer duration may be associated with
better outcomes. However, Johnson et al. 10 had good results
after only 4.5 months. Thus, the appropriate duration of oral
therapy before transition attempt is yet to be determined.
Although 4 of our patients were transitioned very quickly,
based on the literature, it is the authors’ recommendation
that transition be attempted no less than 2 months after the
initiation of oral therapy.
Previous studies have speculated that there may be an
association between a lower mean prostanoid dose and
higher weaning success since that may be reflective of less
severe disease.8,9 Overall our study seems to confirm this
since most of the patients in our study were on lower doses
of prostanoids than in other studies (Table 4). However, we
did not find any significant difference in prostanoid dose
between those in the STand the FT groups and in fact, those
in the ST group were on a higher mean dose of prostanoids
than the FT group. Similar to the study by Johnson et al.10
the mean 6MWD among our patients was4400m and among
the available reports, these 2 series seem to have the
highest success rate.As shown in Table 4, success rate of transitioning has also
been variable with earlier studies reporting a success rate of
only 30–50% using bosentan alone. Our success rate was 70%
and patients were transitioned to different single or a
combination of oral agents. It is interesting to note that all
our patients receiving sildenafil alone or in combination with
bosentan, were able to successfully transition off parenteral
therapy. Johnson et al.10 reported using sildenafil in 2
patients, both of whom also transitioned successfully with
adequate long-term hemodynamics. Although this could be
one of the factors explaining our higher success rate, this
finding requires further validation. It is possible that the
combination of sildenafil with an endothelin receptor
antagonist may allow for a higher success rate with
transitions but this remains speculative.
Most of the transitioned patients were able to maintain
good hemodynamic and functional parameters while on oral
agents at least for an average of 2 years, making this only
the second study10 to report on long-term outcomes in these
patients. Four of our patients in the ST group were doing
well after 3 years follow-up.
In our study, most of the patients that failed to transition
(FT group), did not experience severe long-term hemody-
namic or functional deterioration secondary to this transi-
tion attempt. There was no mortality due to this transition
attempt; however, 1 patient died 2 years after re-institution
of parenteral therapy. Previous studies have reported
worsening clinical status and even mortality in patients
who failed to transition successfully.9,10
This study has several limitations. The patient population
was small and although the transition process was done
according to a predetermined protocol this was an observa-
tional, retrospective study. The small number of patients
may have precluded statistical analysis with enough power
to detect any differences. Many questions remain unan-
swered. Even though we report on relatively long-term
outcomes, it is unclear if these patients will sustain the
clinical and hemodynamic benefit going forward. It is also
not known if the ST patients would have done better had
they been continued on parenteral prostanoids and whether
they will respond to re-institution of these agents should
they deteriorate. Some of these questions may be answered
by future studies.
In summary, carefully selected patients with PH, can be
safely transitioned to oral agents and enjoy continued
clinical stability after a mean follow up of 2 years. Low doses
of prostanoids, mean PAPo40mmHg, 6MWD 4400m, SLE-
PH, and the use of sildenafil could predict a higher likelihood
of successful weaning. These findings require further
confirmation in prospective clinical trials. Since unsuccess-
ful transition to oral agents may, at times, be associated
with unfavorable outcomes, it is our recommendation that
such transition be attempted only in carefully selected
patients, by physicians with extensive experience in caring
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